Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis

Controlled Clinical Trials

Volumn 24, Issue 1, 2003, Pages 16-27

  Chen, Y H Joshua ^a   DeMets, David L ^b   Lan, K K Gordon ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c SANOFI   (France)

Author keywords

Alpha spending function; Composite endpoint; Data monitoring committee (DMC); Interim analysis; Mortality

Indexed keywords

AMLODIPINE; PLACEBO;

ACUTE DISEASE; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MORTALITY; OUTCOMES RESEARCH; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; MORTALITY; RESEARCH DESIGN;

EID: 0037306242     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00306-9     Document Type: Article

References (27)

1. Packer M., Bristow M.R., Cohn J.N.et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
2. Fisher L.D. Carvedilol and the Food and Drug Administration (FDA) approval process. the FDA paradigm and reflections on hypothesis testing Control Clin Trials. 20:1999;16-39.
3. Moye L.A. Endpoint interpretation in clinical trials. the case for discipline Control Clin Trials. 20:1999;40-49.
4. Gong J., Pinheiro J.C., DeMets D.L. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Control Clin Trials. 21:2000;313-329.
5. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 353:1999;2001-2007.
6. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics. 40:1984;1079-1087.
7. Pocock S.J., Geller N.L., Tsiatis A.A. The analysis of multiple endpoints in clinical trials. Biometrics. 43:1987;487-498.
8. Tang D.I., Gnecco C., Geller N.L. Design of group sequential clinical trials with multiple endpoints. J Am Stat Assoc. 84:1989;776-779.
9. Cook R.J. Interim monitoring of bivariate responses using repeated confidence intervals. Control Clin Trials. 15:1994;187-200.
10. Cook R.J. Coupled error spending functions for parallel bivariate sequential tests. Biometrics. 52:1996;442-450.
11. Cook R.J., Farewell V.T. Guidelines for monitoring efficacy and toxicity responses in clinical trials. Biometrics. 50:1994;1146-1152.
12. Jennison C., Turnbull B.W. Group sequential tests for bivariate response. interim analyses of clinical trials with both efficacy and safety endpoints Biometrics. 49:1993;741-752.
13. Lan K.K.G., DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika. 70:1983;659-663.
14. Cox D.R., Oakes D. Analysis of survival data. 1984;Chapman and Hall, London.
15. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
16. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika. 64:1977;191-199.
17. Reboussin DM, DeMets DL, Kim KM, Lan KKG. Programs for computing group sequential boundaries using the Lan-DeMets method. Tech Report, Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison; 1996.
18. Schervish M.J. Multivariate normal probabilities with error bound. Appl Stat. 33:1984;81-94. (Corrections 34:103-104).
19. Packer M., O'Connor C.M., Ghali J.K.et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
20. Gumbel E.J. Bivariate exponential distributions. J Am Stat Assoc. 55:1960;698-707.
21. Lan K.K.G., DeMets D.L. Group sequential procedures. calendar versus information time Stat Med. 8:1989;1191-1198.
22. Whitehead J. Supplementary analysis at the conclusion of a sequential clinical trial. Biometrics. 42:1986;461-471.
23. Whitehead J., Todd S., Hall W.J. Confidence intervals for secondary parameters following a sequential test. J Roy Statist Soc B. 62:2000;731-745.
24. Lin D.Y., Shen L., Ying Z., Breslow N.E. Group sequential designs for monitoring survival probabilities. Biometrics. 52:1996;1033-1041.
25. Lin D.Y. Nonparametric sequential testing in clinical trials with incomplete multivariate observations. Biometrika. 78:1991;123-131.
26. Tsiatis A.A. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika. 68:1981;311-315.
27. Tsiatis A.A. Repeated significance testing for a general class of statistics used in a censored survival analysis. J Am Stat Assoc. 77:1982;855-861.